Lexaria Bioscience Vergangene Ertragsentwicklung
Vergangenheit Kriterienprüfungen 0/6
Lexaria Bioscience's earnings have been declining at an average annual rate of -10.2%, while the Pharmaceuticals industry saw earnings declining at 0.2% annually. Revenues have been declining at an average rate of 0.5% per year.
Wichtige Informationen
-10.2%
Wachstumsrate der Gewinne
15.1%
EPS-Wachstumsrate
| Pharmaceuticals Wachstum der Industrie | 6.0% |
| Wachstumsrate der Einnahmen | -0.5% |
| Eigenkapitalrendite | -50.0% |
| Netto-Marge | -1,180.0% |
| Letzte Ertragsaktualisierung | 31 May 2024 |
Jüngste Aktualisierungen vergangener Leistungen
Recent updates
Aufschlüsselung der Einnahmen und Ausgaben
Wie Lexaria Bioscience Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.
Gewinn- und Umsatzhistorie
| Datum | Einnahmen | Umsatz | Allgemeine und Verwaltungskosten | F&E-Ausgaben |
|---|---|---|---|---|
| 31 May 24 | 0 | -5 | 3 | 2 |
| 29 Feb 24 | 0 | -5 | 3 | 3 |
| 30 Nov 23 | 0 | -6 | 3 | 3 |
| 31 Aug 23 | 0 | -7 | 3 | 4 |
| 31 May 23 | 0 | -7 | 3 | 4 |
| 28 Feb 23 | 0 | -7 | 4 | 3 |
| 30 Nov 22 | 0 | -7 | 4 | 2 |
| 31 Aug 22 | 0 | -7 | 5 | 2 |
| 31 May 22 | 0 | -7 | 5 | 2 |
| 28 Feb 22 | 0 | -7 | 6 | 2 |
| 30 Nov 21 | 0 | -7 | 6 | 2 |
| 31 Aug 21 | 1 | -6 | 5 | 1 |
| 31 May 21 | 1 | -5 | 5 | 1 |
| 28 Feb 21 | 1 | -4 | 4 | 0 |
| 30 Nov 20 | 1 | -4 | 4 | 0 |
| 31 Aug 20 | 0 | -4 | 4 | 0 |
| 31 May 20 | 0 | -4 | 4 | 0 |
| 29 Feb 20 | 0 | -4 | 3 | 1 |
| 30 Nov 19 | 0 | -4 | 4 | 1 |
| 31 Aug 19 | 0 | -4 | 4 | 1 |
| 31 May 19 | 0 | -4 | 4 | 1 |
| 28 Feb 19 | 0 | -6 | 6 | 0 |
| 30 Nov 18 | 0 | -7 | 7 | 0 |
| 31 Aug 18 | 0 | -7 | 7 | 0 |
| 31 May 18 | 0 | -6 | 6 | 0 |
| 28 Feb 18 | 0 | -3 | 3 | 0 |
| 30 Nov 17 | 0 | -2 | 2 | 0 |
| 31 Aug 17 | 0 | -2 | 2 | 0 |
| 31 May 17 | 0 | -1 | 1 | 0 |
| 28 Feb 17 | 0 | -1 | 1 | 0 |
| 30 Nov 16 | 0 | -1 | 1 | 0 |
| 31 Aug 16 | 0 | -1 | 1 | 0 |
| 31 May 16 | 0 | -1 | 1 | 0 |
| 29 Feb 16 | 0 | -2 | 2 | 0 |
| 30 Nov 15 | 0 | -2 | 2 | 0 |
| 31 Aug 15 | 0 | -2 | 2 | 0 |
| 31 May 15 | 0 | -2 | 2 | 0 |
| 28 Feb 15 | 0 | -2 | 2 | 0 |
| 30 Nov 14 | 0 | -2 | 2 | 0 |
| 31 Aug 14 | 0 | -2 | 2 | 0 |
| 31 Jul 14 | 1 | -1 | 1 | 0 |
| 30 Apr 14 | 1 | -1 | 1 | 0 |
| 31 Jan 14 | 1 | 0 | 0 | 0 |
Qualität der Erträge: LEXX is currently unprofitable.
Wachsende Gewinnspanne: LEXX is currently unprofitable.
Analyse von freiem Cashflow und Gewinn
Analyse des Gewinnwachstums in der Vergangenheit
Ergebnisentwicklung: LEXX is unprofitable, and losses have increased over the past 5 years at a rate of 10.2% per year.
Beschleunigtes Wachstum: Unable to compare LEXX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Erträge im Vergleich zur Industrie: LEXX is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.4%).
Eigenkapitalrendite
Hohe Eigenkapitalrendite: LEXX has a negative Return on Equity (-49.98%), as it is currently unprofitable.